LB Pharmaceuticals Inc
LBRXHealthcareNASDAQBiotechnology
Headquartered within the healthcare sector, LB Pharmaceuticals Inc focuses on Biotechnology services and products. LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. With a market capitalization of $860.3M, it sits in small-cap territory. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Market Cap
$860.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-6.68
EPS (TTM)
$-1.36
EPS (Fwd)
$-4.49
ROE
-19.6%
ROA
—
Cash
$365.6M
Total Debt
$3.5M
Free CF
—
52W Change
73.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $365.6M in cash comfortably exceeding the $3.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. ROE of -19.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, LBRX has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LBRX.